Moreover, the loss of TRPM3, TRPV1, TRPV2, and TRPML1 expression has been proposed as a negative prognostic marker for GBM patients, because of their significant and progressive down-regulation as the tumor grade increases. This evidence concerns the gene MCOLN1 and glioblastoma.